Atreca Inc. Stock News

Atreca Announces Licensing Agreement with Zymeworks

SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a uniqu

Atreca (BCEL) stock has fallen 32% today after the stock rose nearly 211% on March 4 following the release of quarterly earnings after the bell the day before.

Clover Health Investments (CLOV) +18%. Monte Rosa Therapeutics (GLUE) +12%. Atreca (BCEL) -30%. Biophytis (BPTS) -14%.

The consensus price target hints at a 310.2% upside potential for Atreca, Inc. (BCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est

Here is how Atreca, Inc. (BCEL) and Indivior PLC (INVVY) have performed compared to their sector so far this year.

Here is how Atreca, Inc. (BCEL) and Indivior PLC (INVVY) have performed compared to their sector so far this year.

Are these penny stocks on your watch list for this week? The post Best Penny Stocks to Watch This Week? 3 For Your Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | Penny

Are these penny stocks on your watch list for this week? The post Best Penny Stocks to Watch This Week?

The shares of micro-cap biotech, Atreca <> have added more than a third in morning hours on Friday to reach the highest level since Dec

Atreca, Inc. (BCEL) CEO John Orwin on Q4 2021 Results - Earnings Call Transcript

Atreca (BCEL) +20%. Alignment Healthcare (ALHC) +16%. DBV Technologies DBVT -22%. Ocugen OCGN -20%.

SAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a uniqu

Atreca press release (BCEL): Q4 GAAP EPS of -$0.79 misses by $0.04.As of December 31, 2021, cash and cash equivalents and investments totaled $148.1 million.